3 Research-Driven Drug Maker, Complex Generics Supplier and Over-the-Counter Medicine Exporter Stocks With a Strong Future Roadmap: Glenmark Pharmaceuticals, Alembic Pharmaceuticals and Marksans Pharma
- October 26, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Glenmark Pharmaceuticals, Alembic Pharmaceuticals and Marksans Pharma: ROE of 11.9% to 28.1% and FY22 to FY26 revenue CAGR of 8.4% to 18.6%. Prices as of 23 Oct 2026.
Quick Answer
The three branded generics and export pharma stocks to watch are Glenmark Pharmaceuticals, Alembic Pharmaceuticals and Marksans Pharma. Their return on equity ranges from 11.9% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.4% to 18.6%. Glenmark Pharmaceuticals has the highest return on equity at 28.1%, while Marksans Pharma has the fastest revenue growth at 18.6% a year. Prices are based on the 23 October 2026 close, and this article is educational, not investment advice.
Branded generics and export pharma stocks let investors follow drug makers that sell medicines in India and abroad. Glenmark Pharmaceuticals, Alembic Pharmaceuticals and Marksans Pharma cover a research-driven drug maker, a complex generics supplier and an over-the-counter medicine exporter.
This list covers three branded generics and export pharma stocks with complete current figures: Glenmark Pharmaceuticals, Alembic Pharmaceuticals and Marksans Pharma. Every figure comes from the latest reported financials and the 23 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Branded Generics and Export Pharma Stocks?
Branded generics and export pharma stocks are listed drug makers that sell branded medicines in India and generics in markets such as the United States and Europe. Their earnings depend on new launches, regulatory approvals, pricing and plant quality.
Branded Generics and Export Pharma Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Glenmark Pharmaceuticals | 2,166.6 | 60,103 | 33.4 | 35.7 | 28.1 | 0.06 |
| Alembic Pharmaceuticals | 760.1 | 14,914 | 21.6 | 35.7 | 11.9 | 0.25 |
| Marksans Pharma | 286.9 | 12,994 | 24.9 | 35.7 | 13.8 | 0.11 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing branded generics and export pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Branded Generics and Export Pharma Stocks Have a Strong Roadmap in India?
Branded generics and export pharma stocks have a strong roadmap in India because the country is a trusted supplier of medicines worldwide and domestic demand for branded treatments keeps rising.
- Complex generics. Injectables and eye care products face less competition.
- Domestic brands. Growing healthcare access lifts branded sales.
- Regulated markets. Approved plants win steady orders from overseas buyers.
Why Glenmark Pharmaceuticals Features Among These Branded Generics and Export Pharma Stocks
Among the branded generics and export pharma stocks on this list, Glenmark Pharmaceuticals is a research-driven pharma company with branded generics in India and other emerging markets, generics in the United States and Europe, and an innovation arm focused on new drugs.
Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%.
In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P/E of 33.4, below the industry P/E of 35.7.
Roadmap: The company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.
What to watch: Track new product launches, progress in the innovation pipeline and balance sheet strength.
Why Alembic Pharmaceuticals Features Among These Branded Generics and Export Pharma Stocks
Among the drug maker company shares on this list, Alembic Pharmaceuticals is a Vadodara-based drug maker that sells generic formulations in the United States, branded medicines in India and active ingredients to other manufacturers.
In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%.
Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7.
Roadmap: The company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.
What to watch: Follow new approvals in the United States, the pace of complex generic launches and domestic growth.
Why Marksans Pharma Features Among These Branded Generics and Export Pharma Stocks
Among the three companies on this list, Marksans Pharma is a Mumbai-based drug maker that produces over-the-counter and prescription formulations at plants in India and sells them in the United Kingdom, the United States, Australia and other markets.
The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7.
Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore.
Roadmap: The company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.
What to watch: Track export growth, new product approvals and plant utilisation.
Glenmark Pharmaceuticals vs Alembic Pharmaceuticals vs Marksans Pharma on Key Financials
The table below sets the three branded generics and export pharma stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Glenmark Pharmaceuticals | 12,472 | 17,443 | 8.7% | 1,362 | 7.8% |
| Alembic Pharmaceuticals | 5,356 | 7,399 | 8.4% | 671 | 9.1% |
| Marksans Pharma | 1,533 | 3,033 | 18.6% | 420 | 13.8% |
Glenmark Pharmaceuticals posts the highest return on equity in this group at 28.1%. Glenmark Pharmaceuticals has the largest FY26 revenue at Rs 17,443 crore, and Marksans Pharma shows the fastest revenue growth with a 18.6% compound annual rate. A useful habit with branded generics and export pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Glenmark Pharmaceuticals | 3,291 | 4,084 | 24.1% |
| Alembic Pharmaceuticals | 1,717 | 2,165 | 26.1% |
| Marksans Pharma | 626 | 866 | 38.5% |
Key Risks to Check Before Investing in Branded Generics and Export Pharma Stocks
Every theme carries risks that deserve a check before any decision. For these branded generics and export pharma stocks, the main points are: Long-term drug maker company shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory checks. Plant inspections can affect approvals.
- Price pressure. Generic prices abroad can fall.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter branded generics and export pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Branded Generics and Export Pharma Stocks
Branded generics and export pharma stocks reward investors who follow new launches, approvals and plant quality together. Glenmark Pharmaceuticals, Alembic Pharmaceuticals and Marksans Pharma each have a clear plan to widen their reach. Based on the 23 October 2026 close, Glenmark Pharmaceuticals trades at Rs 2,166.6, Alembic Pharmaceuticals at Rs 760.1 and Marksans Pharma at Rs 286.9. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these branded generics and export pharma stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track branded generics and export pharma stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are branded generics and export pharma stocks?
Ans. Branded generics and export pharma stocks are listed drug makers that sell branded medicines in India and generics in markets such as the United States and Europe. Their earnings depend on new launches, regulatory approvals, pricing and plant quality. This list looks at three of them, Glenmark Pharmaceuticals, Alembic Pharmaceuticals and Marksans Pharma, using reported FY22 to FY26 financials and the 23 October 2026 closing prices.
Which branded generics and export pharma stocks are covered in this list?
Ans. This list covers Glenmark Pharmaceuticals, Alembic Pharmaceuticals and Marksans Pharma. Based on the 23 October 2026 close, Glenmark Pharmaceuticals traded at Rs 2,166.6, Alembic Pharmaceuticals at Rs 760.1 and Marksans Pharma at Rs 286.9. Their return on equity ranges from 11.9% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.4% to 18.6%.
Why do branded generics and export pharma stocks have a strong future roadmap in India?
Ans. Branded generics and export pharma stocks have a strong roadmap in India because the country is a trusted supplier of medicines worldwide and domestic demand for branded treatments keeps rising. The main drivers are as follows. Complex generics. Injectables and eye care products face less competition. Domestic brands. Growing healthcare access lifts branded sales. Regulated markets. Approved plants win steady orders from overseas buyers. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Glenmark Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P/E of 33.4, below the industry P/E of 35.7. Looking ahead, the company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.
How has Alembic Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7. Looking ahead, the company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.
How has Marksans Pharma performed financially?
Ans. Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7. Looking ahead, the company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.
What risks should investors check before buying branded generics and export pharma stocks?
Ans. Investors should check a few risks before buying branded generics and export pharma stocks. Regulatory checks. Plant inspections can affect approvals. Price pressure. Generic prices abroad can fall. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of branded generics and export pharma stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 23 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.